The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies

Research output: Contribution to journalArticle

Standard

The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. / Robertson, Christopher; Link, CL; Onel, E; Mazzetta, C; Keech, M; Hobbs, Frederick; Fourcade, R; Kiemeney, L; Lee, C; Boyle, Peter; McKinlay, JB.

In: BJU international, Vol. 99, No. 2, 01.02.2007, p. 347-354.

Research output: Contribution to journalArticle

Harvard

Robertson, C, Link, CL, Onel, E, Mazzetta, C, Keech, M, Hobbs, F, Fourcade, R, Kiemeney, L, Lee, C, Boyle, P & McKinlay, JB 2007, 'The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies', BJU international, vol. 99, no. 2, pp. 347-354. https://doi.org/10.1111/j.1464-410X.2007.06609.x

APA

Robertson, C., Link, CL., Onel, E., Mazzetta, C., Keech, M., Hobbs, F., Fourcade, R., Kiemeney, L., Lee, C., Boyle, P., & McKinlay, JB. (2007). The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU international, 99(2), 347-354. https://doi.org/10.1111/j.1464-410X.2007.06609.x

Vancouver

Author

Robertson, Christopher ; Link, CL ; Onel, E ; Mazzetta, C ; Keech, M ; Hobbs, Frederick ; Fourcade, R ; Kiemeney, L ; Lee, C ; Boyle, Peter ; McKinlay, JB. / The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. In: BJU international. 2007 ; Vol. 99, No. 2. pp. 347-354.

Bibtex

@article{b476e464667642b288f36ccd6e1f1762,
title = "The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies",
abstract = "OBJECTIVES To investigate the effect of lower urinary tract symptoms (LUTS) on quality of life (QoL) and to determine its extent across a variety of cultures, and the confounding effects of self-reported comorbidities and demographics. SUBJECTS AND METHODS Data were obtained from two population-based studies in five cities: UREPIK (Boxmeer, the Netherlands; Auxerre, France; Birmingham, UK; and Seoul, Korea) and the Boston Area Community Health (BACH) study (Boston, USA). UREPIK used stratified random samples of men aged 40-79 years. BACH used a multistage stratified cluster sample to randomly select adults aged 40-79 years. QoL was assessed using a standard Medical Outcomes Study-Short Form 12 (SF-12, mental and physical health component scores); LUTS was assessed using the International Prostate Symptom Score (IPSS). The association between QoL and IPSS, associated illnesses, and lifestyle factors was investigated using weighted regression. RESULTS The UREPIK studied 4800 men aged 40-79 years; BACH recruited 1686 men aged 40-79 years. The prevalence of LUTS, defined as an IPSS of >= 8, varied by city (P <0.001), with Auxerre reporting a prevalence (SE) of 18.1 (1.2)%, Birmingham 25.6 (1.5)%, Boston 25.1 (1.6)%, Boxmeer 21.2 (1.3)%, and Seoul 19.0 (1.2)%. Overall, this was similar to the reported rate of high blood pressure. Severe LUTS, defined as an IPSS of >= 20, affected approximate to 3.3% of the age group; this was roughly similar to stroke (2.2%), cancer (4.5%), or heart attack (4.5%) and less than half as much as diabetes (8.6%). A 10-point increase in IPSS was associated with a 3.3 (0.3)-point reduction in SF-12 physical health component score, with the same effect in all cities (P = 0.682 for the interaction test). This was more than the physical health component score reduction caused by cancer, diabetes, or high blood pressure (2 points each), but less than stroke or heart attack (6 points). The comorbidities had no significant impact on SF-12 mental health component score (other than a heart attack, that had a 1.8-point reduction). A 10-point increase in IPSS was associated with a 3.4 (0.6)-point reduction of the mental health component score in the four western cities and a 1.4 (0.3)-point reduction in Seoul. CONCLUSIONS Increasingly severe LUTS is associated with a lower QoL. The effect of moderate LUTS on QoL physical health component score is similar to that of having diabetes, high blood pressure or cancer, while the effect of severe LUTS is similar to a heart attack or stroke. These changes were consistent across cultures. This analysis shows the magnitude and consistency of the effects of LUTS on QoL. While these patients might be seen by several types of practitioners, it is likely that urologists will be in the best position to recognize the true impact of LUTS on a patient's QoL, to be aware of the effects of therapies for LUTS on QoL, and to ensure that colleagues in other disciplines recognize the importance of these symptoms and their treatment.",
keywords = "cultural differences, LUTS, comorbid illness, epidemiology, quality of life",
author = "Christopher Robertson and CL Link and E Onel and C Mazzetta and M Keech and Frederick Hobbs and R Fourcade and L Kiemeney and C Lee and Peter Boyle and JB McKinlay",
year = "2007",
month = feb,
day = "1",
doi = "10.1111/j.1464-410X.2007.06609.x",
language = "English",
volume = "99",
pages = "347--354",
journal = "BJU international",
issn = "1464-4096",
publisher = "Wiley",
number = "2",

}

RIS

TY - JOUR

T1 - The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies

AU - Robertson, Christopher

AU - Link, CL

AU - Onel, E

AU - Mazzetta, C

AU - Keech, M

AU - Hobbs, Frederick

AU - Fourcade, R

AU - Kiemeney, L

AU - Lee, C

AU - Boyle, Peter

AU - McKinlay, JB

PY - 2007/2/1

Y1 - 2007/2/1

N2 - OBJECTIVES To investigate the effect of lower urinary tract symptoms (LUTS) on quality of life (QoL) and to determine its extent across a variety of cultures, and the confounding effects of self-reported comorbidities and demographics. SUBJECTS AND METHODS Data were obtained from two population-based studies in five cities: UREPIK (Boxmeer, the Netherlands; Auxerre, France; Birmingham, UK; and Seoul, Korea) and the Boston Area Community Health (BACH) study (Boston, USA). UREPIK used stratified random samples of men aged 40-79 years. BACH used a multistage stratified cluster sample to randomly select adults aged 40-79 years. QoL was assessed using a standard Medical Outcomes Study-Short Form 12 (SF-12, mental and physical health component scores); LUTS was assessed using the International Prostate Symptom Score (IPSS). The association between QoL and IPSS, associated illnesses, and lifestyle factors was investigated using weighted regression. RESULTS The UREPIK studied 4800 men aged 40-79 years; BACH recruited 1686 men aged 40-79 years. The prevalence of LUTS, defined as an IPSS of >= 8, varied by city (P <0.001), with Auxerre reporting a prevalence (SE) of 18.1 (1.2)%, Birmingham 25.6 (1.5)%, Boston 25.1 (1.6)%, Boxmeer 21.2 (1.3)%, and Seoul 19.0 (1.2)%. Overall, this was similar to the reported rate of high blood pressure. Severe LUTS, defined as an IPSS of >= 20, affected approximate to 3.3% of the age group; this was roughly similar to stroke (2.2%), cancer (4.5%), or heart attack (4.5%) and less than half as much as diabetes (8.6%). A 10-point increase in IPSS was associated with a 3.3 (0.3)-point reduction in SF-12 physical health component score, with the same effect in all cities (P = 0.682 for the interaction test). This was more than the physical health component score reduction caused by cancer, diabetes, or high blood pressure (2 points each), but less than stroke or heart attack (6 points). The comorbidities had no significant impact on SF-12 mental health component score (other than a heart attack, that had a 1.8-point reduction). A 10-point increase in IPSS was associated with a 3.4 (0.6)-point reduction of the mental health component score in the four western cities and a 1.4 (0.3)-point reduction in Seoul. CONCLUSIONS Increasingly severe LUTS is associated with a lower QoL. The effect of moderate LUTS on QoL physical health component score is similar to that of having diabetes, high blood pressure or cancer, while the effect of severe LUTS is similar to a heart attack or stroke. These changes were consistent across cultures. This analysis shows the magnitude and consistency of the effects of LUTS on QoL. While these patients might be seen by several types of practitioners, it is likely that urologists will be in the best position to recognize the true impact of LUTS on a patient's QoL, to be aware of the effects of therapies for LUTS on QoL, and to ensure that colleagues in other disciplines recognize the importance of these symptoms and their treatment.

AB - OBJECTIVES To investigate the effect of lower urinary tract symptoms (LUTS) on quality of life (QoL) and to determine its extent across a variety of cultures, and the confounding effects of self-reported comorbidities and demographics. SUBJECTS AND METHODS Data were obtained from two population-based studies in five cities: UREPIK (Boxmeer, the Netherlands; Auxerre, France; Birmingham, UK; and Seoul, Korea) and the Boston Area Community Health (BACH) study (Boston, USA). UREPIK used stratified random samples of men aged 40-79 years. BACH used a multistage stratified cluster sample to randomly select adults aged 40-79 years. QoL was assessed using a standard Medical Outcomes Study-Short Form 12 (SF-12, mental and physical health component scores); LUTS was assessed using the International Prostate Symptom Score (IPSS). The association between QoL and IPSS, associated illnesses, and lifestyle factors was investigated using weighted regression. RESULTS The UREPIK studied 4800 men aged 40-79 years; BACH recruited 1686 men aged 40-79 years. The prevalence of LUTS, defined as an IPSS of >= 8, varied by city (P <0.001), with Auxerre reporting a prevalence (SE) of 18.1 (1.2)%, Birmingham 25.6 (1.5)%, Boston 25.1 (1.6)%, Boxmeer 21.2 (1.3)%, and Seoul 19.0 (1.2)%. Overall, this was similar to the reported rate of high blood pressure. Severe LUTS, defined as an IPSS of >= 20, affected approximate to 3.3% of the age group; this was roughly similar to stroke (2.2%), cancer (4.5%), or heart attack (4.5%) and less than half as much as diabetes (8.6%). A 10-point increase in IPSS was associated with a 3.3 (0.3)-point reduction in SF-12 physical health component score, with the same effect in all cities (P = 0.682 for the interaction test). This was more than the physical health component score reduction caused by cancer, diabetes, or high blood pressure (2 points each), but less than stroke or heart attack (6 points). The comorbidities had no significant impact on SF-12 mental health component score (other than a heart attack, that had a 1.8-point reduction). A 10-point increase in IPSS was associated with a 3.4 (0.6)-point reduction of the mental health component score in the four western cities and a 1.4 (0.3)-point reduction in Seoul. CONCLUSIONS Increasingly severe LUTS is associated with a lower QoL. The effect of moderate LUTS on QoL physical health component score is similar to that of having diabetes, high blood pressure or cancer, while the effect of severe LUTS is similar to a heart attack or stroke. These changes were consistent across cultures. This analysis shows the magnitude and consistency of the effects of LUTS on QoL. While these patients might be seen by several types of practitioners, it is likely that urologists will be in the best position to recognize the true impact of LUTS on a patient's QoL, to be aware of the effects of therapies for LUTS on QoL, and to ensure that colleagues in other disciplines recognize the importance of these symptoms and their treatment.

KW - cultural differences

KW - LUTS

KW - comorbid illness

KW - epidemiology

KW - quality of life

U2 - 10.1111/j.1464-410X.2007.06609.x

DO - 10.1111/j.1464-410X.2007.06609.x

M3 - Article

C2 - 17313423

VL - 99

SP - 347

EP - 354

JO - BJU international

JF - BJU international

SN - 1464-4096

IS - 2

ER -